DCAF7

Across TCGA pan-cancer cohorts, DCAF7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DCAF7 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DCAF7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DCAF7 expression acts as an unfavorable survival marker.

BLCA, LIHC, and BRCA are the cancer types where DCAF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.236	0.721	<.001	42	view →
LIHC	DFS	Median	All	0.045	0.553	<.001	18	view →
BRCA	DFS	Median	All	0.140	1.000	.001	14	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	DFS	Median	II,III,IV	0.140	0.743	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DCAF7–BLCA (OS)

Open the BLCA breakdown →